<DOC>
	<DOCNO>NCT02851069</DOCNO>
	<brief_summary>The interferon-free combination regimen Paritaprevir/r - Ombitasvir without Dasabuvir ( ABBVIE REGIMEN ) ± Ribavirin ( RBV ) treatment chronic hepatitis C ( CHC ) show safe effective randomize control clinical trial strict inclusion exclusion criterion well control condition . This observational study first effectiveness research examine ABBVIE REGIMEN ± RBV , use accord local label , real world condition Israel clinical practice patient population .</brief_summary>
	<brief_title>Real World Evidence Effectiveness Paritaprevir/r - Ombitasvir , ± Dasabuvir , ± Ribavirin Patients With Chronic Hepatitis C Colombia</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Treatmentnaïve experience adult male female participant confirm CHC , genotype 1 , receive combination therapy interferonfree ABBVIE REGIMEN ± RBV accord standard care line current local label . If RBV coadministered ABBVIE REGIMEN , prescribe line current local label ( special attention contraception requirement contraindication pregnancy ) . Participant must participate intend participate concurrent interventional therapeutic trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Observational Study</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Chronic Hepatitis C genotype 1</keyword>
	<keyword>Sustained Virological Response</keyword>
	<keyword>Paritaprevir/r - Ombitasvir , ± Dasabuvir</keyword>
</DOC>